• Make it like cafepharma, but for different industries: over the years we’ve had suggestions for creating a site similar to cafepharma, but for different industries. Now there is a place. Check out CompanyUnderground for company forums in other industries. Don’t see a company? Request it here. Let your friends and family outside the pharma/medical sales space know they now have a safe, anonymous place to talk.


More right sizeing coming

















































There is going to be a lot of the mgt and marketing from the LGI running of the ship, unfortunately they should be given the gang plank treatment for all dumb decisions. The only question is all the franchises going to have suffer as well..

New tag lines will be:
One final bold kick in the ass.
Or
Be bold or be gone.
Or
Bullshit bingo should be bolded a long time ago.
 












There is going to be a lot of the mgt and marketing from the LGI running of the ship, unfortunately they should be given the gang plank treatment for all dumb decisions. The only question is all the franchises going to have suffer as well..

New tag lines will be:
One final bold kick in the ass.
Or
Be bold or be gone.
Or
Bullshit bingo should be bolded a long time ago.

Avastin crew took GNE into mirrored territories back around '08 or '09. Changed the dynamics of the field and the CS hiring profile. Enter big pharma.
 












Was this Phase 3 trial contingency already baked in the "right sizing"?

"Genentech, Exelixis’ collaborator and sponsor of the IMblaze370 trial, informed the company that the combination of atezolizumab and cobimetinib did not deliver an improvement in overall survival (OS) versus regorafenib." - Business Wire, May 10,2018.
 






This quote from Dr. Jack West of Seattle leave me sleepless -

"Though reportedly leading to a statistically significant improvement in overall survival in the IMpower150 trial (per a press release, data yet to be revealed), the carbo/paclitaxel/bevacizumab/atezolizumab combination adds little other than neuropathy and hair loss to the regimen of carbo/pemetrexed/pembrolizumab already approved by the FDA in advanced non-squamous NSCLC."